ClinicalTrials.gg
CompletedNCT00924989GALACCTICUpdated Nov 20, 2024

A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

A Phase 3 interventional study of OSI-906 and Placebo in Adrenocortical Carcinoma, sponsored by Astellas Pharma Inc. Completed at 35 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Astellas Pharma Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 56 studies in Adrenocortical Carcinoma with a site in United States — 11 open to participants now, 18 under way, none of them phase 3. Adrenocortical Carcinoma · United States.

Enrollment
7th of 49
139 · median 40
Started
2009
with 3 others
Phase 3
5 of 56
none open now
Registered
21st of 56
by date

Among the 56 studies in Adrenocortical Carcinoma with a site in United States, this one is the 7th largest by enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2009, is one of 5 in phase 3, and was the 21st registered.

Adrenocortical Carcinoma

94 studies on the registry are indexed under Adrenocortical Carcinoma; 26 are open to participants now.

Browse Adrenocortical Carcinoma studies →

Open to participants now

11 of the 56 studies in Adrenocortical Carcinoma with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Adrenocortical Carcinoma studies recruiting now, 15 (71%) set no upper age limit and 2 (10%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Adrenocortical Carcinoma with a site in United States, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who received at least 1 but no more than 2 prior drug regimens

Read the detailed description

Patients will be randomized 2:1 to receive either single agent OSI-906 (Arm A) or placebo (Arm B) and will be stratified according to prior systemic cytotoxic chemotherapy for ACC, and Eastern Cooperative Oncology Group (ECOG) performance status, and use of >= 1 oral antihyperglycemic therapy at randomization

03

Conditions studied

  • Adrenocortical Carcinoma

Keywords

  • Adrenocortical carcinoma
  • OSI-906
  • ACC
  • GALACCTIC
  • Insulin-like growth factor-1 receptor (IGF-1R)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adrenocortical carcinoma that is locally advanced or and not amenable to surgical resection.
  • according to (RECIST) (version 1.1).
  • (ECOG) performance status (PS) \<= 2
  • Predicted >= 12 weeks.
  • At least 1 but no more than 2 prior drug regimens (including molecular targeted therapy, systemic cytotoxic chemotherapy, biologics, and/or vaccines) for locally advanced/metastatic ACC.
  • A minimum of 3 weeks must have elapsed between the end of prior treatment and randomization.
  • All patients must have received prior mitotane, either as , adjuvant, or locally advanced/metastatic therapy.
  • Adjuvant and neoadjuvant mitotane therapy will not be counted as prior drug regimens or as systemic cytotoxic chemotherapy.
  • Prior radiation therapy is permitted provided patients have recovered from the acute, toxic effects of radiotherapy prior to randomization.
  • A minimum of 21 days must have elapsed between the end of radiotherapy and randomization.
  • Prior surgery is permitted provided that adequate wound healing has occurred prior to randomization.
  • Fasting glucose \< = 150 mg/dL (8.3 mmol/L).
  • Adequate hematopoietic, hepatic, and renal function defined as follows: >= 1.5 x 10\^9 /L;
  • count >= 100 x 10\^9 /L;
  • \<= 1.5 x (ULN);
  • and ALT \<= 2.5 x ULN, or \<= 5 x ULN if patient has documented liver metastases or received prior mitotane therapy; and
  • Serum creatinine \<= 1.5 x ULN or \<= 2.0 x ULN if the patient has received prior cisplatin.
  • Patients, both males and females, with (ie, menopausal for less than 1 year and not surgically sterilized) must agree to practice effective measures throughout the study.
  • Women of must provide a negative pregnancy test (serum or urine) within 14 days prior to randomization.
  • Patients must provide verbal and written to participate in the study.
  • Radiologically-confirmed progressive disease within 6 months prior to randomization.
  • Concurrent use of non-insulinotropic oral antihyperglycemic therapy is permitted if the dose has been stable for >= 4 weeks at the time of randomization.

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus or Type 2 diabetes mellitus currently requiring insulinotropic or insulin therapy.
  • Prior IGF-1R inhibitor therapy.
  • other than ACC within the past 3 years. Exceptions: resected basal cell or squamous cell carcinoma of the skin; cured in situ cervical carcinoma; cured ductal carcinoma in situ of the breast; and/or cured superficial bladder cancer.
  • History of significant cardiovascular disease unless the disease is well-controlled.
  • Significant cardiac diseases includes second/third degree heart block; ischemic heart disease; mean interval > 450 msec at screening;
  • poorly controlled hypertension; congestive heart failure of (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea).
  • History of cerebrovascular accident (CVA) within 6 months prior to randomization or that resulted in ongoing neurologic instability.
  • Use of drugs that have a risk of causing QT interval prolongation within 14 days prior to Day 1 dosing.
  • Active infection or serious underlying medical condition (including any type of active seizure disorder within 12 months prior to randomization) that would impair the ability of the patient to receive study drug.
  • History of any psychiatric condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide .
  • Pregnant or breast-feeding females.
  • Symptomatic that are not stable, require , are potentially life threatening, or that have required radiation within 28 days prior to randomization.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drug.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Arm A: OSI-906

    150 mg twice daily

    Drug: OSI-906

  • Placebo comparator
    Arm B: Placebo

    Matching placebo twice daily

    Other: Placebo

Interventions

  • Administered orally

    Also known as: linsitinib

  • OtherPlacebo

    Matching placebo administered orally

06

What researchers measure

Primary outcomes

  1. Overall survival of single agent OSI-906 versus placebo

    Time from date of randomization until time of documented death

    Time frame: 33 months

Secondary outcomes

  1. Progression-free survival

    Time from randomization to disease progression based on RECIST version 1.1 or death due to any cause, whichever comes first

    Time frame: 24 months

  2. Disease control rate

    Proportion of patients with a best overall response of complete response (CR), partial response (PR), or stable disease (SD), based on RECIST criteria

    Time frame: 24 months

  3. Best overall response rate

    Proportion of patients with a best overall response of CR or PR based on RECIST criteria

    Time frame: 24 months

  4. Duration of response

    Time from date of the first documented response (CP/PR) to documented progression or death due to underlying cancer

    Time frame: 24 months

  5. Time to deterioration in Quality of Life

    Measured by European Organization for the Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaires

    Time frame: 24 months

  6. Safety assessed via physical exams, vital signs, laboratory assessments, electrocardiograms, and adverse events

    Time frame: 24 months

07

Study locations

35 sites
  • TGen Clinical Research Service at Scottsdale Healthcare
    Scottsdale, Arizona 85258, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • UCLA
    Los Angeles, California 90095, United States
  • University of Colorado Denver Cancer Center
    Aurora, Colorado 80045, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109-2200, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Dartmouth Medical School
    Lebanon, New Hampshire 03756, United States
  • Duke Clinical Cancer Trials Services
    Durham, North Carolina 27710, United States
  • Ohio State University
    Columbus, Ohio 43202, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-6307, United States
  • Mary Crowley Cancer Research Center
    Dallas, Texas 75230, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Royal North Shore Hospital Department of Endocrinology
    St Leonards, New South Wales 2065, Australia
  • St. Joseph's Hospital
    Hamilton, Ontario L8N 4A6, Canada
  • PMH - Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Centre hospitalier de l'Université de Montréal (CHUM)
    Montreal, Quebec H2W 1T8, Canada
  • CHRU Lille, Clinique Endocrinologique Marc Linquette
    Lille, 59037 cedex, France
  • Centre Léon Bérard
    Lyon, 69008, France
  • Institut Paoli-Calmettes
    Marseille, 13273 cedex 09, France
  • Hôpital Cochin-Saint Vincent de Paul
    Paris, 75679 Cedex 14, France
  • CHU Bordeaux - Hôpital Haut-Lévêque
    Pessac, 33604 CEDEX, France
  • Institut Gustave Roussy
    Villejuif, 94805 cedex, France
  • Charite Universitaetsmedizin
    Berlin, 10117, Germany
  • LMU München
    Munich, 80336, Germany
  • Universitaets Klinikum Wuerzburg
    Wuerzburg, 97080, Germany
  • Universita di Torino
    Orbassano, 10043, Italy
  • Università Cattolica del Sacro Cuore
    Rome, 00168, Italy
  • Academic Medical Center
    Amsterdam, 1105 AZ, Netherlands
  • Maxima Medisch Centrum (MMC)
    Eindhoven, 5631 BM, Netherlands
  • Erasmus MC Rotterdam
    Rotterdam, 3015 CE, Netherlands
  • Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie Oddzial w Gliwicach
    Gliwice, 44-101, Poland
  • St. James' University hospital
    Leeds, LS9 7TF, United Kingdom
  • Royal Marsden NHS Trust
    London, SW3 6JJ, United Kingdom
08

References and documents

Publications

  • Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. doi: 10.1016/S1470-2045(15)70081-1. Epub 2015 Mar 18. PubMed 25795408 ↗

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2009 to primary completion in Jul 2012, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2009
First posted
Jun 19, 2009
StartActual
Dec 1, 2009
Primary completionActual
Jul 11, 2012
CompletionActual
Oct 8, 2012
Results delay requested
Jul 10, 2013
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00924989
Responsible party
Sponsor
First posted
Jun 19, 2009
Start date
Dec 1, 2009
Primary completion
Jul 11, 2012
Completion
Oct 8, 2012
Last update
Nov 20, 2024

Study contacts

Medical Director
study director · Astellas Pharma Global Development

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linsitinib

Start the discussion